AR015893A1 - Fragmento estructural derivado de oxietileno, derivados beta-amino y beta-azido de acido carbonico que lo comprenden, su uso para tratar enfermedades comoantagonistas de receptores de endotelina, composiciones farmaceuticas para administracion oral, parenteral e intraparenteral que lo comprenden, co - Google Patents

Fragmento estructural derivado de oxietileno, derivados beta-amino y beta-azido de acido carbonico que lo comprenden, su uso para tratar enfermedades comoantagonistas de receptores de endotelina, composiciones farmaceuticas para administracion oral, parenteral e intraparenteral que lo comprenden, co

Info

Publication number
AR015893A1
AR015893A1 ARP980102873A ARP980102873A AR015893A1 AR 015893 A1 AR015893 A1 AR 015893A1 AR P980102873 A ARP980102873 A AR P980102873A AR P980102873 A ARP980102873 A AR P980102873A AR 015893 A1 AR015893 A1 AR 015893A1
Authority
AR
Argentina
Prior art keywords
substituted
phenyl
beta
nitrogen
alkyl
Prior art date
Application number
ARP980102873A
Other languages
English (en)
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of AR015893A1 publication Critical patent/AR015893A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/12—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un fragmento estructural de la formula I y derivados beta-amino y beta-azido de ácido carbonico que lo comprenden de la formula II en donde R1 representatetrazol o a un grupo -C:O-R en el que R tiene el siguiente significado: a)un residuo OR4, dondeR4 significa. hidrogeno, el cation de un metal alcalino, elcation de un metal alcalinotérreo, un ion amonio orgánico fisiologicamente compatible tal como C1-4-alquilamonio terciario o el ion amonio, C3-8-cicloalquilo,C1-8-alquilo, que puede sersusti tuido CH2-fenilo que puede ser sustituido, un grupo C3-6-alquenilo o C3-6 alquinilo, que puede ser sustituido, fenilo, quepuede ser sustituido, b) un heteroaromático de 5 eslabones ligado por medio de un átomo de nitrogeno, c)es un grupo IIIen el qu e K toma los valores 0, 1 y 2,p los valores 1, 2, 3 y 4 R5 representa C1-4-alquilo, C3-8-cicloalquilo, C3-8-alquenilo, C3-8-alquinilo o fenilo, que puede ser sustituido, d)es un residuo IVen el que R6 significa: C1-4-alquilo,C3-8-alquenilo, C3-8-alq uinilo, C3-8-cicloalquilo, donde estos residuos pueden tener un residuo C1-4-alcoxi,C1-4-alquiltio y/o un residuo de fenilo, C1-4-haloalquilo o fenilo, que puede ser sustituido A NR7R8 o azido, W y Z (que pueden ser igualeso diferentes):nitrogeno o metino con la condicion de que si W y Z = metino, entonces Q = nitrogeno, X nitrogeno o CR9, Y nitrogeno o CR10, Q nitrogeno o CR11, con lacondicion que si Q = nitrogeno, entonces X = CR9 y Y = CR10, R2 y R3 (que pueden seriguales o diferentes) son: fenilo o naftilo, que pueden ser sustituidosfenilo o naftilo, que pueden estar unidos en posicion orto por una union directa a un grupo metileno, etileno o etenileno, a un átomo de oxígeno o azufre o aun grupo SO2, NH- oN-alquilo, C5-6-cicloalquilo , donde estos residuos pueden ser sustituidos, R7 hidrogeno, C1-8-alquilo, C3-8-alquenilo o C3-8-alquinilo,C1-5-alquilcarbonilo, que pueden estar sustituidos, fenilo o naftilo, que pueden ser sustituidoC3-8-cicloalquilo, que pueden ser sustituido, o R7 está unidocon R8 por medio de 4 o 5 grupos CH2 para dar un anillo de 5 o 6 miembros, y R8 es hidrogeno, C2-4-alquilo, o R8 está unido con R7, por medio de 4 o 5 grupos
ARP980102873A 1997-06-19 1998-06-17 Fragmento estructural derivado de oxietileno, derivados beta-amino y beta-azido de acido carbonico que lo comprenden, su uso para tratar enfermedades comoantagonistas de receptores de endotelina, composiciones farmaceuticas para administracion oral, parenteral e intraparenteral que lo comprenden, co AR015893A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19726146A DE19726146A1 (de) 1997-06-19 1997-06-19 Neue ß-Amino und ß-Azidopcarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten

Publications (1)

Publication Number Publication Date
AR015893A1 true AR015893A1 (es) 2001-05-30

Family

ID=7833081

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980102873A AR015893A1 (es) 1997-06-19 1998-06-17 Fragmento estructural derivado de oxietileno, derivados beta-amino y beta-azido de acido carbonico que lo comprenden, su uso para tratar enfermedades comoantagonistas de receptores de endotelina, composiciones farmaceuticas para administracion oral, parenteral e intraparenteral que lo comprenden, co

Country Status (22)

Country Link
EP (1) EP0994861A1 (es)
JP (1) JP2002504130A (es)
KR (1) KR20010013981A (es)
CN (1) CN1261352A (es)
AR (1) AR015893A1 (es)
AU (1) AU8213398A (es)
BG (1) BG104022A (es)
BR (1) BR9810182A (es)
CA (1) CA2294050A1 (es)
CO (1) CO4950605A1 (es)
DE (1) DE19726146A1 (es)
HR (1) HRP980331A2 (es)
HU (1) HUP0002714A3 (es)
ID (1) ID24346A (es)
IL (1) IL133104A0 (es)
NO (1) NO996268L (es)
NZ (1) NZ502319A (es)
PL (1) PL337507A1 (es)
SK (1) SK176299A3 (es)
TR (1) TR199903159T2 (es)
WO (1) WO1998058916A1 (es)
ZA (1) ZA985277B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19806438A1 (de) * 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
DE19858779A1 (de) * 1998-12-18 2000-06-21 Basf Ag Neue ß-Amido und ß-Sulfonamidocarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
DE19924892A1 (de) * 1999-06-01 2000-12-07 Basf Ag Neue Carbonsäurederivate mit arylsubstituierten Stickstoffheterocyclen, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten
WO2002064573A1 (de) * 2001-02-14 2002-08-22 Abbott Gmbh & Co. Kg Neue carbonsäurederivate mit alkylsubstituierten triazinen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
EP1632821B1 (en) 2004-09-01 2012-05-30 Océ-Technologies B.V. Intermediate transfer member with a cleaning member
US7790770B2 (en) * 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
EP2183223A2 (en) * 2007-07-31 2010-05-12 Gilead Colorado, Inc. Metabolites and derivatives of ambrisentan
CN109422664B (zh) * 2017-08-23 2022-02-18 中国科学院福建物质结构研究所 一类干扰素调节剂及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136060A (en) * 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
DE4411225A1 (de) * 1994-03-31 1995-10-05 Basf Ag Verwendung von Carbonsäurederivaten als Arzneimittel
DE19614533A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
ID24346A (id) 2000-07-13
CN1261352A (zh) 2000-07-26
NO996268D0 (no) 1999-12-17
HRP980331A2 (en) 1999-02-28
BG104022A (en) 2001-04-30
IL133104A0 (en) 2001-03-19
KR20010013981A (ko) 2001-02-26
TR199903159T2 (xx) 2000-07-21
CO4950605A1 (es) 2000-09-01
DE19726146A1 (de) 1998-12-24
JP2002504130A (ja) 2002-02-05
CA2294050A1 (en) 1998-12-30
WO1998058916A1 (de) 1998-12-30
HUP0002714A2 (hu) 2001-05-28
AU8213398A (en) 1999-01-04
ZA985277B (en) 1999-12-20
SK176299A3 (en) 2000-06-12
EP0994861A1 (de) 2000-04-26
NZ502319A (en) 2002-03-01
NO996268L (no) 1999-12-17
HUP0002714A3 (en) 2001-07-30
PL337507A1 (en) 2000-08-28
BR9810182A (pt) 2000-08-08

Similar Documents

Publication Publication Date Title
PT1140851E (pt) 4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais
PE20020228A1 (es) Compuestos organicos como inhibidores de 3',5' guanosin monofosfato ciclico fosfodiesterasa
ES2061756T3 (es) Complejos de platino (ii), su preparacion y uso como agentes anti-tumor.
MX167174B (es) Composiciones detergentes suavizadoras
AR015893A1 (es) Fragmento estructural derivado de oxietileno, derivados beta-amino y beta-azido de acido carbonico que lo comprenden, su uso para tratar enfermedades comoantagonistas de receptores de endotelina, composiciones farmaceuticas para administracion oral, parenteral e intraparenteral que lo comprenden, co
ES2062143T3 (es) Derivados de pirrol sustituidos con grupos acriloilo y procedimiento para su preparacion.
ES2095942T3 (es) Derivados de bencenoacetamida inhibidores del vih.
CO5631434A2 (es) Derivados de piridina-carboxamida y su uso como plaguicidas
ES2026669T3 (es) Procedimiento para la preparacion y el uso terapeutico de los beta-d-fenil tioxilosidos.
CO4980887A1 (es) Nueva 3,4-diariltiazolina-2-uno o 2-tiono derivados, sus metodos de preparacion y su uso terapeutico
ES2132882T3 (es) Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina 1.
AR041786A1 (es) Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento
AR017418A1 (es) Una composicion acuosa bombeable y fluida, util como composicion surfactante concentrada y el proceso para prepararla
AR035242A1 (es) Uso de un lipido bioactivo halogenadopara preparar una composicion catartica y compuesto lipido bioactivo halogenado
ES2117132T3 (es) Sales de desferrioxamina-b y su uso como queladores de hierro eficaces por via oral.
GB1229779A (es)
ES2058073T3 (es) Derivados de 5-fluorouracilo.
ES2056811T3 (es) Derivados de cinolina, procedimiento para su preparacion y composiciones herbicidas que los contienen.
CO4930270A1 (es) Derivados heterociclicos de acido carbonico su produccion y aplicacion como antagonistas de receptores deendotelina
ES2036583T3 (es) Iminooxazolidinas, procedimiento de preparacion y metodo de uso.
AR247240A1 (es) Una composicion util para remover recubrimientos polimericos y metodo para remover dichos recubrimientos
AR017052A1 (es) Derivados del acido carboxilico y su uso para preparar medicamentos.
MX9300008A (es) Nucleosidos terapeuticos.
ES2170537T3 (es) Composicion acuosa que neutraliza el fluoruro de amina para pretratamientos de metales que contienen una resina organica y procedimiento de pretratamiento de metales.
PE20010307A1 (es) Derivados de rufomicina utiles como antibioticos

Legal Events

Date Code Title Description
FB Suspension of granting procedure